Business ❯ Pharmaceuticals ❯ Acquisitions

Drug Development

Bispecific Antibodies Obesity Treatments Clinical Trials Brelovitug ALS Treatment

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

The $14-per-share agreement brings Lilly a clinical portfolio targeting chronic inflammation, with closing targeted in the first half of 2026.

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug